Latest News
& Press Releases

A new discovery related to the mechanism of the danger signal adenosine triphosphate could influence how immunomodulators, such as vaccines and allergy medications, are formulated.

With more than 6,600 cases of monkeypox in the United States, the Biden administration declared the viral outbreak a public health emergency as cases continue to rise across the nation.

This week, drugs developed by Neurocrine Biosciences, Akebia, Eliem and Athira all failed to meet expectations in clinical trials.

The agreement will grant Innovent exclusive development and marketing rights to tusamitamab in China, while Sanofi will be entitled to up to $81 million in milestones and royalties.

Gilead snapped up U.K.-based MiroBio in a $405 million deal that will bring its checkpoint agonists and discovery platform under Gilead’s umbrella.

Paul Moore took over as CSO at Zymeworks in July at a pivotal time for the company. He spoke with BioSpace about his ambitions.

New chief executive officers take the reins of companies, while chief financial officers step into their roles overseeing the finances of respective businesses and more.

Lackluster initial results forces Pfizer to discontinue Phase III trial on a potential drug for symptomatic dilated cardiomyopathy (DCM).

Horizon Therapeutics, Eli Lilly, Gilead Sciences and more hit financial road bumps or missed the mark entirely in their Q2 earnings reports.

The big hit has been for its insulin Lispro products. Since January 1, Lispro and Humalog have dropped 26% to $447.1 million in the first quarter.

Experts from U.S. health regulatory agencies have announced plans to conduct a clinical trial to assess the safety and efficacy of TPOXX (tecovirimat) as an antiviral for monkeypox.

Covid-19, aging, stroke, ALS, colorectal cancers and Alzheimer’s disease are all the focus of this week’s top research stories.

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.

• $5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 • $4.5 million of accrued VAT refunds and R&D refundable tax credits from UK subsidiary begin maturing, including $1.9 million VAT cash refund expected in June 2026 • Successful EMA and Australia TGA (ATGA) meetings aligned around use of existing biomarker and pending release of 3-year overall survival data to support Conditional Marketing Authorisations (CMAs) for OST-HER2 in prevention or delay of recurrence in fully-resected, pulmonary metastatic osteosarcoma (“Metastatic Osteosarcoma”) • 2.5-year overall survival data expected to be released during ASCO 2026 • EMA and ATGA have aligned on key design aspects of confirmatory Phase 3 Metastatic Osteosarcoma protocol required to have commenced prior to grant of CMAs or FDA BLA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint • Upcoming U.S. FDA Type C meeting and U.K. MHRA SAM meeting to align with EMA & ATGA prior to Australia Clinical Trial Notification submission for Phase 3, including alignment on 3-year overall survival as a primary clinical efficacy endpoint. U.S. FDA (“FDA”) Pre-BLA meeting to confirm alignment on surrogate and primary clinical efficacy endpoints with EMA/ATGA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint, and seek decisions on rolling review acceptance and RMAT designation following the EMA and U.K. MHRA granting ATMP designation (EMA/MHRA RMAT equivalent) for OST-HER2 in Metastatic Osteosarcoma • OS Animal Health S-1 filing for proposed ‘Go-Public’ transaction and receipt of SEC comments